U.S. diagnostics companies are having a mediocre pandemic. Identifying Covid-19 cases is critical to controlling the spread of the disease, but it’s not lucrative for most, writes rob_cyran.
With no vaccine, finding Covid-19 cases is key. But it’s not lucrative. Extra revenue is being offset by falls in other tests for Quest and rival lab companies and in unrelated businesses for test makers like Abbott.
There’s little time to cash in and plenty of competition.日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
$10 Billion Space Telescope May Be Delayed By Covid-19, Says NASANASA’s long-awaited James Webb Space Telescope (JWST) will likely miss its March 2021 target launch date due to Covid-19
続きを読む »
Cause of death: COVID-19, police violence or racism?Some public health experts are bracing for a spike in COVID-19 cases in the wake of protests against police brutality.
続きを読む »
Dentists extract new fee from patients to keep up with rising COVID-19 costsA growing number of dental offices across the country are charging patients an "infection control fee."
続きを読む »
COVID-19 has now killed more people in the U.K. than The BlitzONS figures show that 44,401 deaths involving COVID-19 occurred in England and Wales up to May 22, surpassing the number of people who died in the blitz.
続きを読む »
Lyft Says Demand Picking Up as Covid-19 Restrictions EaseThe company said demand for rides climbed in recent weeks as people began venturing out following Covid-19 lockdowns but remains well below levels seen a year earlier.
続きを読む »
WHO committee recommends continued study of hydroxychloroquine as a potential Covid-19 treatmentThe coronavirus pandemic has brought countries to a standstill. Here's the latest updates on Covid-19 cases, deaths, government responses and more.
続きを読む »